Key facts
- Global biotech giants are strengthening ties with Chinese drugmakers.
- Competition for jumbo IPOs is intensifying.
Global biotechnology leaders are expanding their relationships with pharmaceutical companies in China. Simultaneously, the market is witnessing an acceleration in the race for large-scale initial public offerings (IPOs). This dual development suggests a dynamic period for both international pharmaceutical collaborations and the capital markets.